← Browse by Condition
Medical Condition

minimal residual disease

Total Trials
2
Recruiting Now
2
Trial Phases
Phase 2

ClinicalMetric tracks all active clinical trials for minimal residual disease sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — minimal residual disease Clinical Trials

How many clinical trials are currently recruiting for minimal residual disease?
ClinicalMetric currently tracks 2 actively recruiting clinical trials for minimal residual disease, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 2. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for minimal residual disease?
minimal residual disease research spans Phase 2 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a minimal residual disease clinical trial?
Eligibility criteria for minimal residual disease trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
1
Top Sponsors
IRCCS Azienda Ospedaliero-Universitaria di Bologna 1 trial
M.D. Anderson Cancer Center 1 trial

Recruiting Clinical Trials

NCT06885476
Recruiting
Infusion of Alloreactive nk Cells for Mrd-positive Aml Patients
Enrollment
22 pts
Location
Italy
Sponsor
IRCCS Azienda Ospedaliero-Univ...
View Trial →
NCT07136077 Phase 2
Recruiting
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
Enrollment
20 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
View Trial →

Related Conditions

acute myeloid leukemia (1) natural killer cell (1) adjuvant chemotherapy (1) colorectal cancer (1) fruquintinib (1) tislelizumab (1) ctdna (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology